
Eltrombopag (Promacta), a small molecule thrombopoietin receptor (TPOR) agonist, has received a Breakthrough Therapy designation from the FDA for the treatment of cytopenias in patients with severe aplastic anemia (SAA) who have had insufficient response to immunosuppressive therapy.